In an era of big pharmaceutical companies merging together to reach an even greater critical mass, it may be expected that very little opportunities, if any, remain for smaller companies. Nevertheless...
In an era of big pharmaceutical companies merging together to reach an even greater critical mass, it may be expected that very little opportunities, if any, remain for smaller companies. Nevertheless, while running challenging projects pioneering the clinical frontiers, oversized companies may skip some details and fail to fully exploit the potential of already achieved solutions or may disregard the investigation of alternative options. With the aim to fill this gap, IBSA has developed a series of niche-oriented proprietary technologies allowing a quality upgrading of available widely-used molecules and therapeutic solutions. This attitude has been coupled with full competence on the whole range of activities typical of a pharmaceutical company, from basic research to pre-clinical and clinical development, high quality manufacturing, regulatory expertise and direct marketing of proprietary products. Fine-tuned on clinical needs, IBSA remains fully committed to improve compliance, safety and efficacy of its proprietary medicines.